Common Contracts

3 similar Underwriting Agreement contracts by Dror Ortho-Design, Inc., Perspective Therapeutics, Inc., Vaxcyte, Inc.

DROR ORTHO-DESIGN, INC. [ ] SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE PRE-FUNDED WARRANTS TO PURCHASE [ ] SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE
Underwriting Agreement • February 3rd, 2026 • Dror Ortho-Design, Inc. • Dental equipment & supplies • New York
Perspective Therapeutics, Inc. 39,576,088 Shares of Common Stock Pre-Funded Warrants to Purchase 6,598,046 Shares of Common Stock UNDERWRITING AGREEMENT Dated: February 2, 2026
Underwriting Agreement • February 3rd, 2026 • Perspective Therapeutics, Inc. • Pharmaceutical preparations • New York
VAXCYTE, INC. (a Delaware corporation) 11,000,000 Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • February 2nd, 2026 • Vaxcyte, Inc. • Biological products, (no disgnostic substances) • New York

Vaxcyte, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), Jefferies LLC (“Jefferies”), Leerink Partners LLC (“Leerink Partners”), and Evercore Group L.L.C. (“Evercore”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA, Jefferies, Leerink Partners and Evercore are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.001 per share, of the Company (“Common Stock”), set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 1,650,000 addit